BioGaia subsidiary IBT takes rapid steps in development of a drug for premature infants

Infant Bacterial Therapeutics (IBT) aims to develop a unique orphan drug to
prevent the fatal disease necrotising enterocolitis (NEC). The project has
proceeded faster than previously scheduled and according to the updated
development plan IBT expects to run two clinical trials within the next three
years.
Please see enclosed pdf for full press release.
For additional information please contact
Peter Rothschild, President, BioGaia: 46 8 555 293 00

Staffan Strömberg, President IBT: 46 8 410 145 55
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com